Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Determinants of patient screen failures in Phase 1 clinical trials.

Mckane A, Sima C, Ramanathan RK, Jameson G, Mast C, White E, Fleck S, Downhour M, Von Hoff DD, Weiss GJ.

Invest New Drugs. 2013 Jun;31(3):774-9. doi: 10.1007/s10637-012-9894-7. Epub 2012 Nov 8.

PMID:
23135779
2.

Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors.

Gounder MM, Nayak L, Sahebjam S, Muzikansky A, Sanchez AJ, Desideri S, Ye X, Ivy SP, Nabors LB, Prados M, Grossman S, DeAngelis LM, Wen PY.

J Clin Oncol. 2015 Oct 1;33(28):3186-92. doi: 10.1200/JCO.2015.61.1525. Epub 2015 Aug 17.

3.
4.

Eligibility criteria in randomized phase II and III adjuvant and neoadjuvant breast cancer trials: not a significant barrier to enrollment.

Filion M, Forget G, Brochu O, Provencher L, Desbiens C, Doyle C, Poirier B, DuRocher M, Camden S, Lemieux J.

Clin Trials. 2012 Oct;9(5):652-9. doi: 10.1177/1740774512456453.

PMID:
23060323
5.

Study of cohort-specific consent and patient control in phase I cancer trials.

Daugherty CK, Ratain MJ, Minami H, Banik DM, Vogelzang NJ, Stadler WM, Siegler M.

J Clin Oncol. 1998 Jul;16(7):2305-12.

PMID:
9667244
6.

Tezacitabine Hoechst Marion Roussel.

Seley KL.

Curr Opin Investig Drugs. 2000 Sep;1(1):135-40. Review.

PMID:
11249589
7.

A Case-Control Study Brings to Light the Causes of Screen Failures in Phase 1 Cancer Clinical Trials.

Kempf E, Lemoine N, Tergemina-Clain G, Turpin A, Postel-Vinay S, Lanoy E, Soria JC, Massard C, Hollebecque A.

PLoS One. 2016 May 5;11(5):e0154895. doi: 10.1371/journal.pone.0154895. eCollection 2016.

8.

Reasons why patients fail screening in Indian breast cancer trials.

Mahajan P, Kulkarni A, Narayanswamy S, Dalal J, Halbe V, Patkar S, Bhatt A.

Perspect Clin Res. 2015 Oct-Dec;6(4):190-3. doi: 10.4103/2229-3485.167100.

9.

Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret Hospital.

Ho J, Pond GR, Newman C, Maclean M, Chen EX, Oza AM, Siu LL.

BMC Cancer. 2006 Nov 8;6:263.

10.

Potential cytochrome P-450 drug-drug interactions in adults with metastatic solid tumors and effect on eligibility for Phase I clinical trials.

Wisinski KB, Cantu CA, Eickhoff J, Osterby K, Tevaarwerk AJ, Heideman J, Liu G, Wilding G, Johnston S, Kolesar JM.

Am J Health Syst Pharm. 2015 Jun 1;72(11):958-65. doi: 10.2146/ajhp140591.

11.

Communication about the risks and benefits of phase I pediatric oncology trials.

Hazen RA, Zyzanski S, Baker JN, Drotar D, Kodish E.

Contemp Clin Trials. 2015 Mar;41:139-45. doi: 10.1016/j.cct.2015.01.015. Epub 2015 Jan 29.

12.

Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies.

Wong SE, North SA, Sweeney CJ, Stockler MR, Sridhar SS.

Clin Genitourin Cancer. 2017 Sep 8. pii: S1558-7673(17)30274-4. doi: 10.1016/j.clgc.2017.08.019. [Epub ahead of print]

PMID:
28993132
13.

Characteristics and outcome of pediatric patients enrolled in phase I oncology trials.

Kim A, Fox E, Warren K, Blaney SM, Berg SL, Adamson PC, Libucha M, Byrley E, Balis FM, Widemann BC.

Oncologist. 2008 Jun;13(6):679-89. doi: 10.1634/theoncologist.2008-0046.

14.

Relationship between objective responses in phase I trials and potential efficacy of non-specific cytotoxic investigational new drugs.

Sekine I, Yamamoto N, Kunitoh H, Ohe Y, Tamura T, Kodama T, Saijo N.

Ann Oncol. 2002 Aug;13(8):1300-6.

PMID:
12181255
15.

Factors influencing time to determination of the recommended phase 2 dose in phase 1 clinical trials.

Caldwell S, Sima C, Jameson G, Fleck S, Weiss GJ.

Am J Clin Oncol. 2013 Apr;36(2):146-50. doi: 10.1097/COC.0b013e31824370a3.

PMID:
22314002
16.

Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies.

Postel-Vinay S, Aspeslagh S, Lanoy E, Robert C, Soria JC, Marabelle A.

Ann Oncol. 2016 Feb;27(2):214-24. doi: 10.1093/annonc/mdv550. Epub 2015 Nov 16. Review.

PMID:
26578728
17.

Impact of Eligibility Criteria on Participant Enrollment for a Randomized Clinical Trial of Gonorrhea Treatment.

Long JE, Wierzbicki MR, Hook EW 3rd.

Sex Transm Dis. 2017 Jun;44(6):362-364. doi: 10.1097/OLQ.0000000000000604.

PMID:
28499287
18.

Does phase 1 trial enrollment preclude quality end-of-life care? Phase 1 trial enrollment and end-of-life care characteristics in children with cancer.

Levine DR, Johnson LM, Mandrell BN, Yang J, West NK, Hinds PS, Baker JN.

Cancer. 2015 May 1;121(9):1508-12. doi: 10.1002/cncr.29230. Epub 2014 Dec 29.

19.

AN-9 (Titan).

Hobdy E, Murren J.

Curr Opin Investig Drugs. 2004 Jun;5(6):628-34. Review.

PMID:
15242252
20.

American society of clinical oncology--41st annual meeting. Immunology.

Shah S, Yager N.

IDrugs. 2005 Jul;8(7):528-30. No abstract available.

PMID:
15973554

Supplemental Content

Support Center